期刊文献+

人全血他克莫司浓度高效液相色谱-质谱法检测方法学的建立及性能评价 被引量:2

Measurement of tacrolimus in blood with the method of high performance fiquid chromatographymass spectrometry
原文传递
导出
摘要 目的建立全血他克莫司高效液相色谱-质谱(HPLC-MS)的检测方法。方法液液萃取的方法从血中提取出他克莫司,然后用高效液相色谱-质谱的方法分离并检测他克莫司的浓度;同时进行标准曲线、线性范围、最低检测限、精密度、回收率及比对实验。结果方法标准曲线回归方程为Y=0.2464X+0.0082,R^2=0.9996;线性范围为0.100—40.000ng/ml,回归方程为Y=1.0294x-0.035,R^2=0.9998;最低检测限为0.100ng/ml;以浓度为0.300、4.004、8.008、16.016ng/ml的4种浓度样本测定不精密度(CV),其批内CV分别为4.67%、2.78%、3.22%、3.58%,其总CV分别为5.67%、3.16%、3.97%、4.29%;用浓度为0.300、4.004、8.008、16.016ng/ml4种标准品进行回收实验,其回收率分别为95.67%、97.00%、95.88%、98.30%;与酶联免疫吸附试验(ELISA)方法进行比对,回归方程为Y=1.0172x+0.3742,相关系数R^2=0.9630,2种方法相关性较好,ELISA方法的测定值较HPLC—MS方法的测定值高,差异有统计学意义(P〈0.01)。结论HPLC-MS方法具有方便、快速、准确和成本低的优点,可用于对全血中他克莫司的临床监测和实验研究。 Objective To develop a simple, precise, and specific method for measurement of tacrolimus in whole blood. Methods Tacrolimus was extracted from the blood samples of 40 patients treated with tacrolimus by liquid-liquid extraction. Then high performance liquid chromatography-mass spectrometry (HPLC/MS) was used, with ascomycin as internal marker, to isolate the tacrolimus and measure the concentration thereof. The standard curve was drawn. The linearity of quantitative measurement was determined. Detection limits test, CV test, and recovery test were performed. ELISA was used simultaneously. The results of these 2 methods were compared. Results A good standard curve was drawn based on the results of HPLC/MS assay(y =0. 2464x +0. 0082,R2 =0. 9996). The detected data were highly related to the detected concentrations. The linearity range was 0. 100 - 40. 000 ng,/ml ( y = 1. 0294x - 0. 035, R^2 =0. 9998). The detection limit of the assay was 0. 100 ng,/ml. The CV values by this assay were basically 〈5%. The recovery rate ranged 95.67% -98.30% for tacrolimus over the range 0. 300 - 16. 016 ng/ml. There was a linear correlation (y = 1. 0172x + 0. 3742,R^2 = 0. 9630) between the assay results by HPLC/MS to ELISA in blood. The measurement value of ELISA was ( 19 ±9), significantly higher than that of HPLC/MS ( 18 ± 9, P 〈 0. 01 ). Conclusion This newly developed method of HPLC,/MS is simple, precise, and specific and with lower cost, it can be used in the clinical practice and experimental study on tacrolimus.
出处 《中华医学杂志》 CAS CSCD 北大核心 2008年第32期2290-2294,共5页 National Medical Journal of China
关键词 色谱法 高压液相 质谱分析法 血药浓度 他克莫司 方法学评价 Chromatography, high pressure liquid Mass spectrometry Plasma concentration Tacrolimus Evaluation of measurement methods
  • 相关文献

参考文献13

  • 1Alak AM. Measurement of tacrolimus (FK506) and its metabolites: a review of assay development and application in theraputic drug monitoring and pharmacokinetic studies. Ther Drug Monit, 1997,19:338-351.
  • 2Zhang Q, Simpson J , Aboleneen HI. A specific method for the measurement of FK506 in human whole blood by liquid chromatography/tandem mass spectrometry. Ther Drug Monit, 1997, 19:470-476.
  • 3丁少波,胡敏燕.他可莫司血药浓度监测[J].中国医院药学杂志,2002,22(3):147-149. 被引量:14
  • 4Iwasaki K. Metabolism of tacrolimus ( FK506 ) and recent topics in clinical pharmacokinetics. Drug Metab Pharmacokinet, 2007, 22 : 328-335.
  • 5Cogill JL, Taylor PJ, Westley IS, et al. Evaluation of the tacromlimus Ⅱ micropaticle enzyme immunoassay ( MEIA Ⅱ ) in liver and renal transplant recipients. Clin Chem, 1998, 44: 1942-1946.
  • 6van Hooff JP, Boots JM, van Duijnhoven EM, et al. Dosing and management guidelines for tacrolimus in renal transplant patients. Transplant Proc, 1999,31 (7A) :54S-57S.
  • 7王立明,闵志廉,朱有华,高春芳,陆慧琦,周梅生,姚亚成.肾移植受者应用他克莫司治疗窗浓度的探讨[J].中华器官移植杂志,2000,21(3):145-146. 被引量:26
  • 8徐新军,刘皋林,张正行.他克莫司治疗的监测方法[J].国外医药(抗生素分册),2001,22(5):222-227. 被引量:9
  • 9National Committee for Clinical laboratory Standards. EP6-A Evalution of the linearity of quantitative measurenment procedures : a statistical approach; Approved guideline. Pennsylvania: Wayne, 2003.
  • 10National Committee for Clinical laboratory Standards. EP17-A Protocols for determination of limits of detection and limits of quantitation: Approved guideline-second edition. Pennsylvania: Wayne, 2004.

二级参考文献38

  • 1[1]Kino T, Hatanaka H, Hashimoto M, et al. FK-506, a novel immunosuppressant isolated from a Streptomycies.1. Fermentation, isolation, and physico-chemical and biological characteristics. [J]. J Antibiot, 1987,40:1249
  • 2[2]Ireland RE, Liu LB, Roper TU, et al. Total synthesis of FK506. [J]. Tetrahedron, 1997, 53 (39): 13257
  • 3[3]Caroline M, Spencer, Karen L, et al. Tacrolimus:an update of its pharmacology and clinical efficacy in the management of organ transplantation. [J]. Drugs, 1997, 54(6): 925
  • 4[4]Dasgupta A,Timmerman TG. Therapeutic monitoring of tacrolimus using liquid chromatography. [J]. J Liq Chromatogr, 1995,18(20) :4029
  • 5[5]Venkataramanan R, Swaminathan A, Prasad T,et al. Clinal pharmacokinetics of tacrolimus. [J]. Clin Pharmacokinet.1995,29(6) :404
  • 6[6]Lampen A, Christians U, Guengerich FP, et al.Metabolism of the immunosuppressant FK in the small intestine: cytochrome P450, drug interactions and interindividual variability. [J]. Drug Metab Dispos, 1995,23 (12):1315
  • 7[7]Winkler M ,Christians U,Stoll K, et al. Comparison of different assays for the quantitation of FK506 levels in blood or plasma. [J]. Ther Drug Monit ,1994,16(3):281
  • 8[8]Warty V, Zuckermans, Venkataramanan R, et al.Tacrolimus analysis:A comparison of different methods and matrices. [J]. Ther Drug Monit, 1995,17 (2) : 159
  • 9[9]Winkerler M, Christians U, Gonschior AK. Evauation of the new Pro-Trac tacrolimus, monoclonal whole blood ELISA for monitoring tacrolimus levels in patients after kidney , heart and liver transplant. [J]. Ther Drug Monit, 1995,17: 430
  • 10[10]Freeman DJ,Stawecki M,Howson B. Stability of FK506in whole blood samples. [J]. Ther Drug Monit, 1995,17(3): 266

共引文献42

同被引文献12

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部